By Tyler Hoar Featured Post Photo: ©David Turgeon GENERAL FORECAST It looks to be a flight year for many species in Eastern Canada. With mostly very poor crops in the boreal forest from central Quebec...

Georges Seurat's once-mocked painting Bathers at Asnières is both an "exquisite distillation of the very essence of summer" and "a modern wonder in the art of seeing".

Ban the over-use of single use plastics.

Chimeric antigen receptor (CAR) T-cell therapy has shown impressive efficacy in treating relapsed or refractory multiple myeloma. Nonetheless, its availability is substantially restricted by complex m...

YouTube video by NuttyRiv3r

DLL3, B7H3 and Her3 are compelling tumor antigens to target with cancer therapeutics. They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attackin...

In 1986 - nearly 40 years ago - the first antibody therapy was FDA-approved: muromonab-CD3 (Orthoclone OKT3®), a murine monoclonal antibody targeting human CD3 expressed on T cells. This therapy was u...

AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.

YouTube video by Jack Straw From Wichita

Aleta Bio recently announced that their scientists have created, characterized and validated novel classes of Immune Cell Engager therapeutics including T Cell Engagers (TCE) and CAR T Cell Engagers (...

By Paul Rennert Aleta’s CSO and Co-Founder Paul Rennert talks about the company’s recent announcement that their scientists created, characterized, and validated novel classes of Immune Cell Engager...

Aleta Bio recently announced that their scientists have created, characterized and validated novel classes of Immune Cell Engager therapeutics including T Cell Engagers (TCE) and CAR T Cell Engagers (...

UK pharma group acquires Belgium’s EsoBiotec as it announces EU has approved Imfinzi lung cancer drug

This Open Access 8th ed. of the EBMT book addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy

There were waves of interest in this therapeutic space at ASCO in June 2024 and around the JP Morgan healthcare conference in January 2025. Here we take a look at the hope and the hype behind the PD1/...

YouTube video by Paul Rennert

In 1986 - nearly 40 years ago - the first antibody therapy was FDA-approved: muromonab-CD3 (Orthoclone OKT3®), a murine monoclonal antibody targeting human CD3 expressed on T cells. This therapy was u...

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel) 1 ; Company believes results do not support a competitive benefit-risk profile for patients. CARGO ...